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A two-step synthetic scheme has been employed for the synthesis of 4-naphtho [2, 1-b] furan-2-yl-chromen-2-ones/4-(3-
alkoxy-naphtho-[2,3-b]furan-2-yl)-chromen-2-ones(angular/linear naphthofuranyl coumarins). The reactions have been 
monitored by TLC and structures of the intermediates and the target compounds have been ascertained by IR, NMR and 
mass spectral data. Both the isomeric naphthofuranyl coumarins have been found to exhibit anti-inflammatory activity 
comparable to asprin but when tested for analgesic activity, angularly fused naphthofuranyl coumarins show better activity 
comparable to asprin whereas linear naphthofuranyl coumarins are less active. 
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Oxygen containing heterocycles such as coumarins 
and naphtho[b]furans are structural components of a 
large number of biologically active natural and 
synthetic compounds. Coumarins are naturally 
occurring δ-lactones occurring extensively in the plant 
kingdom. Their application in the field of medicinal 
chemistry
1,2
, in the study of bio-chemical 
mechanisms
3
 and in the design of fluorescent probes
4
 
has attracted researchers in these areas. Coumarin 
derivatives with different heterocyclic moieties linked 
at position C-4 are well known for their biological 
properties
5-7
 and industrial applicability
8-10
. Coumarin 







Regio-isomeric naphtho[2,1-b]- and [2,3-b]-furans 
are also present in many biologically important 
natural products
13
. Naphthofuran derivatives exhibit 














 activities (Figure 1). 
The broad spectrum of therapeutic values of coumarin 
and naphthofuran ring system prompted us to 
synthesize the title compounds and screen them for 
analgesic and anti-inflammatory activities. Although a 
lot of synthetic methodologies for the synthesis 
naphtho[b]furans have been reported in the 
literature
20
, the development of new approaches to 
their syntheses, employing efficient routes is currently 
a popular research area
21,22
. 
Results and Discussion 
Synthesis and characterization 
In view of the above mentioned important biological 
properties of 4-heterocyclic coumarins and 
2-heteroaryl naphthofurans, it was thought worthwhile 
to synthesize isomeric naphtho furanyl coumarins and 
study its biological properties. The sequences of 
reactions are presented in Scheme I and Scheme II. The 




was used as a commercial sample and 2-hydroxy 
3-naphthoic esters were prepared using alcohol and 
conc. H2SO4 from 2-hydroxy-3-naphthoic acid. 
Reaction of 4-bromomethyl coumarins (1) with 
equimolar proportions of 2-hydroxy-1-
naphthaldehyde (2) resulted in a facile nucleophilic 
displacement at room temperature resulting in the 
formation of the ethers (3). In the next step, under 
refluxing conditions in ethanol and in the presence of 
K2CO3, ethers (3) underwent an intramolecular 
carbanion addition followed by dehydration leading to 
the formation of 4-2' naphtho[2,1-b]furanyl coumarins 
(4). Extension of this methodology to the esters of 2-
hydroxy-3-naphthoic acid (5) lead to the formation of 
3-alkoxy 4-2'-naphtho [2,3-b]furanyl coumarins (6). 




Intermediacy of the naphthofuranol (P) is 
supported by our earlier work
24
 wherein coumarin 
linked dihydro-benzofuranols have been isolated 
(Figure 2). In case of ester 5 elimination of water 
takes place rather than alcohol which looks more 
favorable, thus yields 6. Formation of these 
compounds is supported by the spectral methods 
employed for their characterization. 
IR spectrum of 6-methyl-4-naphtho [2, 1-b] furan-





H NMR spectrum exhibited six 
doublets at 8.22, 8.05, 7.99, 7.87, 7.74 and 7.21 ppm 
correspond to Ar-H of Coumarin and naphthyl 
moieties. Two triplets at 7.56 and 7.67 ppm 
correspond to Ar-H of naphthyl moiety. Three 
singlets at 7.84, 7.26 (merged with solvent peak) and 
 
 








Scheme II — Synthesis of 4-(3-alkoxy-naphtho [2, 3-b] furan-2-yl) chromen-2-ones (6a-g) 
 




6.86 ppm correspond to Coumarin-C5-H, furan C3-H 
and Coumarin-C3-H respectively. The ESI mass 
spectrum exhibited a peak at 327.2 (M+H) which 
confirmed the formation of 4a (R= -CH3). 
IR spectrum in the case of 4-(3-Methoxy-naphtho 
[2,3-b] furan-2-yl)-6-methyl-chromen-2-one, (6a) 





exhibited singlets at 7.77 and 6.90 ppm corresponding 
to coumarin C5 and C3 protons. Methyl and methoxy 
protons appeared at 2.51 and 3.85 ppm as singlet 
each. Four doublets at 8.24, 8.00, 7.88 and 7.59 ppm 
correspond to Ar-H of Coumarin and naphthyl 
moieties. 2 triplets at 7.42 and 7.33 ppm correspond 
to Ar-H of naphthyl moiety. Two singlets at 8.08 and 
7.68 correspond to Naphthyl C1 and C4-H. ESI mass 
spectrum exhibited a peak at 357 (M+H) confirmed 
the formation of (R and R’= -CH3). 
 
Biological Evaluation 
Anti-inflammatory activity by carrageenan induced 
rat paw edema and analgesic activity by rat caudal 
immersion in hot water were carried out 
simultaneously in same group of animals
25
. 
Measurement of paw edema volume followed by 
reaction to thermal stimuli (tail withdrawal) in 
seconds were recorded at 0, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 
h and 6 h, after injection of carrageenan. Percentage 
inhibition of paw edema and percentage of analgesia 
for test drugs as well as for standards are presented in 
Table I and Table II. Results obtained were analyzed 
by one-way ANOVA followed by Dunnet’s multiple 
comparison tests. 
Anti-inflammatory activity of naphthofuranyl 
coumarins derivatives are shown in Table I and 
Figure 3 and it was observed that at 2 hr compounds 
(4c), (4d), (4e), (4f), (6a), (6f) significantly (P<0.01) 
inhibited the carrageenan induced ratpaw edema 
(42.85%, 50%, 50%, 42.85%, 42.85% and  
42.85%) at the dose of 150 mg/kg b.w. by oral  
(p. o) route, when compared with control group. 
Analgesic activity of naphthofuranyl coumarins 
derivatives are shown in Table II and Figure 4, it was 
observed that at 3 hr naphthofuranyl coumarins 
derivatives (compounds 4c, 4d, 4e and 4f) 
significantly (P< 0.01) inhibited the threshold pain 
(113.64%, 126.11%, 127.89% and 98.51%) of rat by 
tail immersion at the dose 150 mg/kg b.w. by oral  
(p. o) route, when compared with control group. 
 
 
Figure 2 — Plausible Mechanism for the formation of Naphthofuranyl coumarins 
 
Table I — Percentage inhibition of paw edema by naphthofuranyl coumarins in carrageenan induced paw edema model 
Groups R R' 
% inhibition of paw edema at different time intervals 
0 h 0.5 h 1 h 2 h 3 h 4 h 5 h 6 h 
Aspirin   0 37.5 45.454 57.142 58.333 50 50 57.142 
4a 6-CH3 H 0 12.5 27.272 35.714 33.333 30 25 28.571 
4b 7-CH3 H 0 25 27.272 35.714 33.333 30 25 14.285 
4c 5,7-CH3 H 0 25 27.272 42.857 41.666 40 25 28.571 
4d 7,8-CH3 H 0 37.5 45.454 50 41.666 40 37.5 28.571 
4e 6-OCH3 H 0 25 45.454 50 50 40 37.5 42.857 
4f 5,6-benzo H 0 12.5 18.181 42.857 41.666 40 37.5 28.571 
6a 6-CH3 OCH3 0 25 36.363 42.857 41.666 40 37.5 28.571 
6b 7-CH3 OCH3 0 25 27.272 28.571 25 30 25 28.571 
6f 6-CH3 OC2H5 0 25 36.363 42.857 33.333 40 25 28.571 
6g 7,8-CH3 OC2H5 0 25 27.272 28.571 25 30 25 14.285 






Figure 3 — Effect of naphthofuranyl coumarins derivatives on 








Melting points were determined by  
open capillary method and are uncorrected. Thin layer 
chromatography (TLC) was performed using silica-
gel GF254 plates. IR spectra (KBr disc) were 
recorded on a Nicolet-5700 FT-IR spectrophotometer. 





C-NMRin CDCl3.Mass spectra were recorded 
using LCMS- MPS-SCIEX-API-2000 and GCMS-
QP2010SD Shimadzu. Heraus CHN rapid analyser 
has been used for elemental analysis. Unless stated 
otherwise, chemicals were all purchased from 
commercial sources and used without treatment. 
 
General procedure for the preparation of  
2-hydroxy-naphthalene-1-carboxylic acid methyl 
and ethyl esters 
A mixture of 2-hydroxy 1-naphthaldehyde  
(18.8 g, 0.1 mol) and 50 mL of absolute methanol/ 
ethanol is taken in a round bottom flask and stirred for 
about 10 min at room temperature. 5 mL of conc. 
H2SO4 is added drop wise to the reaction mixture with 
stirring and allowed to stir for another 10 min., 
followed by reflux on water bath temperature  
for about 8-10 h. The viscous reaction mixture 
allowed to cool at room temperature, shining  
crystals separates out, filtered and washed  
with alcohol and dried. Compound crystallized  
from alcohol. 
 
General procedure for the preparation of isomeric 
naphthofuranyl coumarins (4a-4g, 6a-6g) 
To a dry 100 mL flask equipped with a stir bar was 
added substituted 4-bromo methyl coumarins 
(0.004 mol), 2-hydroxy 1-naphthaldehyde/2-hydroxy-
naphthalene-3-carboxylic acid methyl/ethyl esters 
(0.004 mol), anhydrous K2CO3 (0.82 g, 0.006 mol) 
and absolute ethanol (30 mL). The reaction mixture 
was stirred for 15 min at room temperature, followed 
by reflux for 12-16 h. Reaction on completion, as 
monitored on TLC, alcohol was concentrated and the 
solution was poured onto crushed ice. The crude solid 
obtained was filtered, washed with dil. HCl, then with 
water and finally with minimum amount of alcohol 
and crystallized from alcohol. All synthesized 





NMR and MS. 
Table II — Percentage inhibition of pain threshold by naphthofuranyl coumarins in tail immersion model 
Groups 
% Inhibition of pain threshold 
0 hr 30 min 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr 
Aspirin 42.116 58.571 89.887 128.783 131.666 80.562 77.749 67.836 
4a 17.49 47.857 57.752 89.614 76.333 43.734 50.895 56.432 
4b 18.574 38.809 45.617 86.943 102.333 74.424 37.595 59.356 
4c 1.9438 42.619 78.651 113.649 106.666 56.010 58.567 56.725 
4d 19.222 48.333 85.842 126.112 104.666 80.306 47.314 68.713 
4e 31.749 52.142 79.550 127.893 115 74.168 50.639 69.883 
4f 15.550 7.857 9.438 98.516 67.666 52.941 41.687 57.017 
6a 6.2634 24.523 19.550 79.525 77.666 15.601 62.659 68.713 
6b 5.1835 25.952 26.966 72.997 60 25.575 24.296 43.859 
6f 12.742 23.571 24.719 72.997 65.333 15.601 52.941 40.058 
6g 11.447 32.857 39.101 58.456 48.666 25.575 47.058 52.631 




Characterization data for the compounds 4(a-g) 
and 6(a-g) 
6-Methyl-4-naphtho [2,1-b] furan-2-yl-chromen-







H NMR (300 MHz, CDCl3) 
δ:8.22 (d, 2H, J= 9 Hz), 8.03 (q, 2H,  
J = 9 Hz), 7.89-7.84 (m, 2H, Ar-H), 7.74 (d,1H, J= 9 
Hz), 7.67 (t, 1H, J= 9 Hz), 7.57 (d,1H, J= 9 Hz), 
7.21(d, 1H, J= 6 Hz), 6.86 (s,1H, C3-H of 
coum.),2.45 (s, 6H, 2CH3 of coum.). MS (ESI+) m/ z 
=327 (M+H). Anal. calc. for C22H14O3: C, 80.97;  
H, 4.32. Found C, 80.88; H, 4.60. 
 
7-Methyl-4-naphtho [2,1-b] furan-2-yl-chromen-







H NMR  
(300 MHz, CDCl3) δ: 8.22 (dd, 2H, J= 9 Hz), 8.00 (d, 
1H, J= 6 Hz ), 7.88 (d, 2H, J= 9 Hz), 7.74 (d, 1H,  
J= 9 Hz),7.68 (t, 1H, J= 9 Hz ), 7.57( t, 1H, J= 9 Hz), 
7.23 (m, 2H, ), 6.87 (s, 1H, C3-H of coum.), 2.51  
(s, 3H, CH3 of coum.). MS (ESI+) m/ z = 327 (M+H). 
Anal. calc. for C22H14O3:C, 80.97; H, 4.32. Found C, 
80.80; H, 4.42. 
 
5,7-Dimethyl-4-naphtho [2,1-b] furan-2-yl-






H NMR (300 MHz, 
CDCl3) δ: 8.20 (s, 1H, J= 9 Hz), 8.04 (q, 2H, J=9 Hz), 
7.86-7.82 (m, 2H), 7.76 (d, 1H, J= 9 Hz),7.68 (1H, 
J=9 Hz),7.82 (d, 1H, J= 6 Hz), 7.26-7.20 (m, 1H), 
6.86 (s, 1H, C3-H of coum.), 2.47 (s, 6H, 2CH3 of 
coum.). MS (ESI+) m/ z= 341 (M+H). Anal. Calc. for 
C23H16O3: C, 81.16; H, 4.74. Found C, 81.20; H, 4.19. 
 
7,8-Dimethyl-4-naphtho [2,1-b] furan-2-yl-
chromen-2-one (4d):Yield:1.00 g (74%). mp 190-192 
o




H NMR (300 MHz, 
CDCl3) δ: 8.22 (s, 1H, J= 9 Hz), 8.02 (q, 2H, J=9 Hz), 
7.89-7.85 (m, 2H), 7.74 (d, 1H, J= 9 Hz),7.67 (1H, 
J=9 Hz),7.88 (d, 1H, J= 6 Hz), 7.23-7.20 (m, 1H), 
6.85 (s, 1H, C3-H of coum.), 2.44 (s, 6H, 2CH3 of 
coum.). MS (ESI+) m/ z= 341(M+H). Anal. Calc. for 
C23H16O3: C, 81.16; H, 4.74. Found C, 81.44; H, 4.20. 
 
6-Methoxy-4-naphtho [2,1-b] furan-2-yl-
chromen-2-one (4e): Yield:0.96 g (70%).mp 200
o
C. 




H NMR (300 MHz, 
CDCl3) δ:8.22 (d, 1H, J=6 Hz), 8.00 (d,1H, J= 6 Hz), 
7.90-7.82 (m, 3H), 7.75 (d, 1H, J= 9 Hz), 7.68 (t, 1H, 
J= 9 Hz), 7.57 (t, 1H, J=9 Hz),7.38 (d, 1H, J=9 Hz), 
7.22 (d, 1H, J = 9 Hz), 6.92 (s,1H, C3-H), 3.92 (s, 3H, 
OCH3 of coum.). MS (ESI+) m/ z = 343 (M+H). Anal. 











H NMR (300 MHz, CDCl3) 
δ:8.38-7.22 (m,13H), 6.85 (s, 1H, C3-H of coum.). 
MS (ESI+) m/z= 363 (M+H). Anal. Calc. for 
C25H14O3 C, 82.86; H, 3.89. Found C, 82.72; H, 3.66. 
 
4-Naphtho [2,1-b] furan-2-yl-benzo[h]chromen-







H NMR (300 MHz, CDCl3) 
δ:8.35-7.20 (m,13H), 6.84 (s, 1H, C3-H of coum.). 
MS (ESI+) m/z= 363 (M+H). Anal. Calc. for 
C25H14O3 C, 82.86; H, 3.89. Found C, 82.30; H, 3.36. 
 
4-(3-Methoxy-naphtho [2,3-b] furan-2-yl)-6-
methyl-chromen-2-one (6a): Yield:0.99 g (70%). mp 
216-219 
o




H NMR (300 
MHz, CDCl3) δ: 8.26-7.27 (m, 9H), 6.90 (s, 1H, C3-H 
of coum.), 3.85 (s, 3H, OCH3 of coum.), 2.51 (s, 3H, 
CH3 of coum.). MS (ESI+) m/ z = 357 (M+H). Anal. 




methyl-chromen-2-one (6b): Yield:0.96 g (68%). mp 
224-225 
o




H NM R (300 
MHz, CDCl3) δ: 8.24-7.22 (m, 9H), 6.84 (s, 1H, C3-H 
of coum.), 3.86 (s, 3H, OCH3 of coum.), 2.47 (s, 3H, 
CH3 of coum.). MS (ESI+) m/ z=357 (M+H). Anal. 
Calc. forC23H16O4: C, 77.52; H, 4.53. Found C, 77.42; 
H, 4.20. 
 
4-(3-Methoxy-naphtho [2,3-b] furan-2-yl)-7, 8-
dimethyl-chromen-2-one (6c): Yield:1.04g (70%). 
mp230-232 
o





(300 MHz, CDCl3) δ: 8.20-7.20 (m, 8H), 6.86 (s, 1H, 
C3-H of coum.),3.88 (s, 3H, OCH3 of coum.), 2.47  
(s, 6H, 2CH3 of coum.). MS (ESI+) m/ z = 371(M+H). 
Anal. Calc. for C24H18O4: C, 77.82; H, 4.90. Found C, 
77.89; H, 4.20. 
 
1-(3-Methoxy-naphtho [2,3-b] furan-2-yl)-
benzo[f]chromen-3-one (6d): Yield:0.99 g (63%). 
mp242-248 
o





(300 MHz, CDCl3) δ: 8.24-7.19 (m, 12H), 6.84 (s, 1H, 
C3-H of coum.), 3.90 (s, 3H, OCH3 of coum.). MS 




(ESI+) m/ z= 393(M+H). Anal. Calc. forC26H16O4: C, 
79.58; H, 4.11. Found C, 79.42; H, 4.20. 
 
4-(3-Methoxy-naphtho [2, 3-b] furan-2-yl)-benzo 
[h]chromen-2-one (6e): Yield: 0.94 g (60%). mp250-
252 
o




H NMR (300 MHz, 
CDCl3) δ: 8.28-7.20 (m, 12H), 6.85 (s, 1H, C3-H of 
coum.), 3.90 (s, 3H, OCH3 of coum.). MS (ESI+) m/ z 
= 393(M+H). Anal. Calc. for C26H16O4: C, 79.58;  
H, 4.11. Found C, 79.42; H, 4.20. 
 
4-(3-Ethoxy-naphtho [2, 3-b] furan-2-yl)-6-
methyl-chromen-2-one (6f): Yield:1.02 g (69%). 
mp252-255
o




H NMR  
(300 MHz, CDCl3) δ:8.25-7.24 (m, 9H), 6.84 (s, 1H, 
C3-H of coum.),4.48 (q, J= 9.0 Hz, 2H, OCH2), 1.47 
(t, J= 9.0 Hz, 3H, CH3), 2.45 (s, 3H, CH3 of coum.). 
MS (ESI+) m/ z = 371(M+H). Anal. Calc. 
forC24H18O4: C, 77.82; H, 4.90. Found: C, 77.02;  
H, 4.36. 
 
4-(3-Ethoxy-naphtho [2, 3-b] furan-2-yl)-7, 8-








(300 MHz, CDCl3) δ: 8.22-7.19 (m, 8H), 6.85 (s, 1H, 
C3-H of coum.), 4.47 (q, J= 9.0 Hz, 2H, OCH2), 1.47 
(t, J= 9.0 Hz, 3H, CH3), 2.44 (s, 6H, 2CH3 of coum.). 
MS (ESI+) m/ z = 385 (M+H). Anal. Calc. for 




Albino Wistar rats (170-220 g) and Swiss albino 
mice (20-25 g) of either sex were used in the study. 
The inbred colonies of rats were purchased from 
Venkateshwara enterprises, Bangalore. They were 
acclimatized to controlled conditions of temperature 
(23 ± 2 
o
C), 30-70% humidity and 12 hr light-dark 
cycles. The animals were randomized into 
experimental and control groups and housed four each 
in sanitized polypropylene cages containing sterile 
paddy husk as bedding. They had free assessed to 
standard pellets as basal diet and water ad libitum. All 
the studies conducted were approved by Institutional 
Animal Ethical Committee (IAEC), SET’s College of 
Pharmacy, Dharwad, Karnataka (REG. No. 
112/1999/CPCSEA). According to prescribed 
guidelines of committee for the purpose of Control 
and Supervision of Experiments in Animals 
(CPCSEA), Government of India. 
Conclusions 
(i) Naphthofuranyl coumarins have been synthesized 
in two regioisomeric forms using similar synthetic 
protocol. 
(ii) This methodology is adoptable for any allylic and 
benzylic type of halides to get regioisomeric 
naphthofurans. 
(iii) Both the regioisomeric forms of naphthofuranyl 
coumarins showed good anti-inflammatory and 
analgesic activities but less than standard Asprin. 
(iv) Angular naphthofuranyl coumarins exhibited 
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